



OHIO DEPARTMENT OF MEDICAID
Pharmacy & Therapeutics Committee
Ohio Department of Medicaid, 50 W Town Street
January 10th, 2018
10:00 A.M.

AGENDA

- I. Call to Order
- II. Introductions
- III. Administrative Matters
 - a. Conflict of Interest Statements
 - b. P&T By-Law Review
- IV. Department of Medicaid Update
- V. Approval of October 4th, 2017 Meeting Minutes
- VI. Drug Class Announcements
- VII. Interested Party Presentations
- VIII. Preferred Drug List (PDL) Proposal
 - a. Fiasp[®] (insulin aspart), Novo Nordisk, Endocrine Agents: Diabetes-Insulin
 - b. Symproic[®] (naldemedine), Purdue Pharma, Gastrointestinal Agents: Opioid-Induced Constipation
 - c. Kevzara[®] (sarilumab), Sanofi-Aventis, Immunomodulator Agents for Systemic Inflammatory Disease
 - d. Siliq[™] (brodalumab), Valeant, Immunomodulator Agents for Systemic Inflammatory Disease
 - e. Tremfya[™] (guselkumab), Janssen, Immunomodulator Agents for Systemic Inflammatory Disease
 - f. Vosevi[™] (sofosbuvir, velpatasvir, and voxilaprevir), Gilead Sciences, Infectious Disease Agents: Antivirals-Hepatitis C Agents
 - g. AirDuo[™] Respiclick[®] (fluticasone-salmeterol), Teva, Respiratory Agents: Beta-Adrenergic Agonists-Inhaled, Long Acting
 - h. Trelegy Ellipta (fluticasone, umeclidinium and vilanterol), GlaxoSmithKline LLC, Respiratory Agents: COPD
 - i. Armonair[™] Respiclick[®] (fluticasone), Teva, Respiratory Agents: Glucocorticoid Agents-Inhaled
 - j. Haegarda[®] (C1 esterase inhibitor), CSL Behring, Respiratory Agents: Hereditary Angioedema
- IX. Other Business
 - a. Review of rosuvastatin utilization in Ohio Medicaid.
- X. Next Meeting Dates:
 - a. TBD
- XI. Adjournment